Background: Thromboxane A 2 (TXA 2 ) induces platelet aggregation and promotes thrombus formation. Although ginsenoside Ro (G-Ro) from Panax ginseng is known to exhibit a Ca 2þ -antagonistic antiplatelet effect, whether it inhibits Ca 2þ -dependent cytosolic phospholipase A 2 (cPLA 2a ) activity to prevent the release of arachidonic acid (AA), a TXA 2 precursor, is unknown. In this study, we attempted to identify the mechanism underlying G-Ro-mediated TXA 2 inhibition. Methods: We investigated whether G-Ro attenuates TXA 2 production and its associated molecules, such as cyclooxygenase-1 (COX-1), TXA 2 synthase (TXAS), cPLA 2a , mitogen-activated protein kinases, and AA.
Introduction
Platelets are activated via breakdown of phosphatidylinositol 4,5-bisphosphate in the plasma membrane (PM) to inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DG) by phospholipase C (PLC) [1] . IP 3 mobilizes Ca 2þ from the endoplasmic reticulum to the cytoplasm, and Ca 2þ activates Ca 2þ /calmodulin-dependent protein kinase [2] . Apart from phosphorylating pleckstrin by binding to protein kinase C, DG acts as a donor of arachidonic acid (AA) [3] , a precursor of thromboxane A 2 (TXA 2 ) [4] . TXA 2 is an autacoid produced from AA by the actions of cyclooxygenase-1 (COX-1) and TXA 2 synthase (TXAS) and initiates thrombogenesis [5e7] . Antithrombotic drugs, such as aspirin, imidazole, and indomethacin, block TXA 2 production by inhibiting COX-1 or TXAS activity [8] .
Mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38-MAPK, are phosphorylated in thrombin-activated human platelets [9e11] . Phosphorylated p38-MAPK and ERK2 induce TXA 2 production [12e14]. Moreover, the phosphorylation of p38-MAPK is essential for the activation of cytosolic phospholipase A 2a (cPLA 2a ), leading to AA release [14] .
Thrombin elevates the intracellular Ca 2þ level, leading to the translocation of cPLA 2a from the cytosol to the PM. Subsequently, p38-MAPK activates cPLA 2a by phosphorylating it at Ser 505 [15] .
Therefore, it may be beneficial to evaluate the antiplatelet potential of a compound on TXA 2 production in relation to phosphorylation of MAPKs. Roots of Panax (P) ginseng are used in traditional Oriental medicine. In a previous study, we reported that total saponin from Korean Red Ginseng inhibits both COX-1 and TXAS to reduce the production of TXA 2 [16] ; however, its individual components have not yet been evaluated. Therefore, we evaluated the effects of ginsenoside Ro (G-Ro), an oleanane-type saponin (Fig. 1) in P. ginseng, on the production of TXA 2 along with its associated enzymes and signaling molecules. ), antiphosphor-p38-MAPK, anti-phosphor-JNK (1/2), anti-p38-MAPK, anti-JNK (1/2), anti-COX-1, anti-TXAS, anti-rabbit IgG-horseradish peroxidase conjugate, and lysis buffer were obtained from Cell Signaling Technology (Beverly, MA, USA). PD98059, SB203580, SP600125, and anti-b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyvinylidene difluoride membrane and enhanced chemiluminescence solution were purchased from GE Healthcare (Piscataway, NJ, USA). Human AA EIA kit was obtained from Cusabio (Wuhan, Hubei, China).
Materials and methods

Materials
Preparation of washed human platelets
Human platelet-rich plasma with acidecitrateedextrose solution (0.8% citric acid, 2.2% sodium citrate, 2.45% glucose) was procured from Korean Red Cross Blood Center (Changwon, Korea). It was centrifuged for 10 min at 1,300Âg to obtain the platelet pellets. The platelets were washed twice using a washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 5.5 mM glucose, and 1 mM Na 2 EDTA, pH 6.5) and resuspended in a suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 0.49 mM MgCl 2 , 5.5 mM glucose, and 0.25% gelatin, pH 6.9) to a final concentration of 5 Â 10 8 cells/mL. All the aforementioned procedures were performed at 25 C to preserve platelet activity. These experiments were approved (PIRB12-072) by the National Institute for Bioethics Policy Public Institutional Review Board (Seoul, Korea).
Determination of platelet aggregation
Platelets (10 8 cells/mL) were preincubated, with or without GRo, in a CaCl 2 (2 mM) solution for 3 min at 37 C. They were stimulated with thrombin (0.05 U/mL) and allowed to aggregate for 5 min in an aggregometer (Chrono-Log Corporation). Platelet aggregation rate was determined as an increase in light transmission. G-Ro was dissolved in the platelet suspension buffer (pH 6.9), and MAPK inhibitors were dissolved in 0.1% dimethyl sulfoxide. of total protein by SDS-PAGE (6%, 1.5 mm). A Polyvinylidene difluoride membrane was used for protein transfer. The primary and secondary antibodies were diluted 1:1,000 and 1:10,000, respectively. The membranes were visualized using an enhanced chemiluminescence solution solution. The degrees of phosphorylation were analyzed using the Quantity One 1-D analysis software, Version. 4.5 (Bio-Rad, Hercules, CA, USA).
Measurement of TXB 2
Because TXA 2 is unstable and gets converted spontaneously to TXB 2 , it was quantified by determining the TXB 2 content [4] . After platelet aggregation, the reaction was terminated by adding icecold EDTA (5 mM) and indomethacin (0.2 mM) to prevent the metabolism of AA to TXA 2 . The amount of TXB 2 , a stable metabolite of TXA 2 , was determined using a TXB 2 EIA kit according to the procedure described by the manufacturer.
Isolation of microsomal fraction
Washed platelets (10 8 cells/mL), suspended in a buffer (pH 7.4) with 1% protease inhibitor, were sonicated 10 times at 100% sensitivity for 20 s on ice (Bandelin, HD2070, Germany) to obtain the platelet lysate. The microsomal fraction, containing endoplasmic reticulum membrane, was obtained by ultracentrifugation at 105,000Âg for 1 h at 4 C [16].
AA release
The reaction was terminated after platelet aggregation, and the aggregates were centrifuged at 200Âg at 4 C for 10 min. AA in the supernatant was quantified using an AA EIA kit (Cusabio), and the absorbance was measured at 450 nm using a Synergy HT multimode microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).
COX-1 activity assay
The microsomal fraction of platelets was preincubated with aspirin (500 mM), a positive control, or with various concentrations of G-Ro and other reagents at 37 C for 30 min. COX-1 activity was assayed with a COX-1 fluorescence assay kit (Cayman Chemical Co).
TXAS activity assay
The microsomal fraction of platelets was preincubated with ozagrel (11 nM, IC 50 ), a positive control, or with various concentrations of G-Ro and other reagents at 37 C for 5 min. The reaction was initiated by adding prostaglandin H 2 , and the samples were incubated at 37 C for 1 min; the reaction was terminated by adding citric acid (1 M). After neutralization with 1 N NaOH, the amount of TXB 2 was determined using a TXB 2 EIA kit according to the procedure described by manufacturer.
Statistical analyses
All experimental results are indicated as the mean AE standard deviation accompanied by the number of trials. Significant differences were determined by analysis of variance followed by the NewmaneKeuls multiple comparisons method. All statistical analyses were conducted using the SPSS 21.0.0.0 software (SPSS, Chicago, IL, USA). A p value < 0.05 was considered to be statistically significant.
Results
Effects of G-Ro on platelet aggregation
We used thrombin at a dose of 0.05 U/mL, which induces maximum human platelet aggregation [17] to stimulate the platelets in this study. Thrombin increased platelet aggregation up to 92.5 AE 1.2%. However, G-Ro reduced the thrombin-induced platelet aggregation in a dose-dependent manner (Fig. 1B) .
Effects of G-Ro on TXA 2 production
We determined whether G-Ro reduced platelet aggregation by inhibiting TXA 2 production (by measuring the TXB 2 level). As shown in Fig. 1C , thrombin increased TXB 2 level (49.2 AE 1.6 ng/10 8 platelets), whereas G-Ro dose-dependently (50e300 mM) reduced the TXB 2 level that was induced by thrombin; G-Ro (300 mM)
inhibited the thrombin-mediated elevation in TXB 2 level by 94.9%.
Effects of G-Ro on activities of COX-1 and TXAS
We evaluated the activities of COX-1 (70 kDa) and TXAS (58 kDa) in the microsomal fraction to investigate whether they contributed to the reduction in TXB 2 by G-Ro (Fig. 2A, lane 2) . COX-1 activity in the absence of G-Ro (negative control) was 2.3 AE 0.1 nmol/mg protein. However, G-Ro dose-dependently (50e300 mM) reduced its activity (Fig. 2B) ; at 300 mM, COX-1 activity was reduced by 26 .4% of that of the negative control. TXAS activity in the absence of G-Ro (negative control) was 220.8 AE 1.8 ng/mg protein/min. However, G-Ro dose-dependently (50e300 mM) reduced its activity (Fig. 2C) ; at 300 mM, TXAS activity was reduced by 22.9% of that of the negative control. We observed that G-Ro (300 mM) reduced COX-1 (26.4%) and TXAS (22.9%) activities to similar extents.
Effects of G-Ro on cPLA 2a phosphorylation and AA release
The inhibitory effect of G-Ro (300 mM) on TXB 2 production (94.9%, Fig. 1C ) was significantly higher than those on COX-1 (26.4%, Fig. 2B ) and TXAS (22.9%, Fig. 2C ) activities. This suggested that G-Ro might also inhibit AA release, a precursor of TXA 2 , from PM phospholipids to reduce TXA 2 production in thrombin-activated platelets.
Because Ca 2þ -dependent cPLA 2a is activated by phosphorylation [18] and releases AA from PM phospholipids in thrombin-activated human platelets [10] , we investigated the effect of G-Ro on the phosphorylation of cPLA 2a . As shown in Fig. 3A , G-Ro inhibited the thrombin-mediated phosphorylation of cPLA 2a (Ser 505 ) in a dosedependent manner as it is reported that cPLA 2a is activated by phosphorylation of cPLA 2a at Ser 505 [18, 19] . At 300 mM, G-Ro inhibited the thrombin-induced cPLA 2a (Ser 505 ) phosphorylation by 96.5% (Fig. 3A) . Moreover, it reduced the thrombin-induced AA release in a dose-dependent manner (Fig. 3B) ; at 300 mM, it inhibited AA release by 61.1% of that induced by thrombin (2159.2 AE 29.0 ng/10 8 platelets).
Effects of G-Ro on the phosphorylation of MAPKs
Platelets contain MAPKs, such as ERK, JNK, and p38-MAPK [20] , that phosphorylate Ser 505 of cPLA 2a [10,14,18,19,21e23] . Therefore, we investigated whether G-Ro inhibited the phosphorylation of cPLA 2a (Ser 505 ) in thrombin-activated human platelets. Thrombin-mediated p38-MAPK phosphorylation (Fig. 4A, lane 2) was dose-dependently (50e300 mM) inhibited by G-Ro (Fig. 4A, lanes 3e6) . Furthermore, the p38-MAPK inhibitor, SB203580, attenuated the thrombin-induced phosphorylation of p38-MAPK (Fig. 4A, lane 7) . Thrombin phosphorylated JNK1 (46 kDa), but not JNK2 (54 kDa), as shown (Fig. 4B, lane 2) . G-Ro attenuated the thrombin-induced phosphorylation of JNK1 in a dose-dependent manner (Fig. 4B,  lanes 3e6 ). The inhibitor of JNK, SP600125, inhibited the phosphorylation of both JNK1 and JNK2 in thrombin-activated human platelets (Fig. 4B, lane 7) .
3.6. Effects of MAPK inhibitors on cPLA 2a phosphorylation, AA release, and TXA 2 production Furthermore, we investigated whether MAPK inhibitors inhibited the phosphorylation of cPLA 2a . Thrombin extensively phosphorylated cPLA 2a ; however, it was inhibited by SB203580 (40 mM). Nevertheless, PD98059 (40 mM) and SP600125 (40 mM) did not influence the thrombin-induced cPLA 2a phosphorylation (Fig. 5A ).
Among the MAPK inhibitors, only SB203580 (40 mM), a p38-MAPK inhibitor, strongly inhibited the thrombin-mediated cPLA 2a phosphorylation. This suggested that p38-MAPK induces cPLA 2a phosphorylation and may stimulate TXA 2 production by promoting AA release. Therefore, we tested this hypothesis using SB203580.
We observed that it inhibited the thrombin-induced AA release and TXA 2 production by 75.2% and 91.6%, respectively (Figs. 5B, 5C ).
Discussion
The autacoid TXA 2 , produced in platelets, constricts blood vessels and initiates thrombogenesis [7, 24, 25] . P. ginseng compounds, such as ginsenoside Rp1 [26] , panaxadiol, and panaxatriol saponins [27e29], inhibit TXA 2 production and attenuate platelet aggregation. In this study, we evaluated whether G-Ro inhibits thrombininduced platelet aggregation by decreasing TXA 2 production and investigated the mechanisms underlying the attenuation of AA release. We sought to identify the TXA 2 antagonistic potential of GRo for development into an antiplatelet agent.
G-Ro inhibited TXA 2 production to abolish thrombin-induced platelet aggregation. We determined the activities of COX-1 (70 kDa) and TXAS (58 kDa) in the microsomal fraction, which has the highest activity of cytochrome c reductase (an endoplasmic reticulum marker enzyme) to justify this inhibitory effect [16] . G-Ro reduced the production of TXA 2 more than it reduced the activities of COX-1 and TXAS, suggesting that it may also inhibit AA release by cPLA 2a and AA utilization by COX-1 and TXAS in thrombin-activated platelets. As expected, G-Ro strongly inhibited both thrombin- produce DG and IP 3 from phosphatidylinositol 4,5-bisphosphate in the PM. DG is hydrolyzed to AA and glycerol via the DGe and monoacylglycerolelipase pathway [1] . Accordingly, we cannot rule out GRo-mediated inhibition of the PLC b /DGelipase/monoacylglycerole lipase pathway to reduce AA release in thrombin-activated platelets.
In the present study, G-Ro inhibited the activities of both the AA release enzyme (cPLA 2a ) and AA utilization enzymes (COX-1 and TXAS) to decrease the thrombin-induced TXA 2 production. These enzymes are known to be activated by phosphorylated MAPKs [12e 14,19e21,32e39] . Therefore, we used MAPK inhibitors to investigate whether G-Ro requires inhibition of thrombin-phosphorylated MAPKs for attenuating TXA 2 production. SB203580 (a p38-MAPK inhibitor) inhibited the thrombin-induced p38-MAPK phosphorylation, cPLA 2a phosphorylation, AA release, and TXA 2 production. These results confirm that thrombin-phosphorylated p38-MAPK increases AA release and TXA 2 production by promoting cPLA 2a phosphorylation.
Similar to SB203580, G-Ro attenuated thrombin-induced p38-MAPK phosphorylation, cPLA 2a phosphorylation, AA release, and TXA 2 production. Therefore, we can assume that G-Ro inhibits thrombin-induced AA release and TXA 2 production by preventing the phosphorylation of both p38-MAPK and cPLA 2a . Moreover, G-Ro is reported to inhibit the thrombin-mediated phosphorylation of ERK2 [30] and JNK1. However, G-Ro failed to inhibit AA release through suppression of ERK2-and JNK1-induced cPLA 2a phosphorylation in thrombin-activated platelets. Furthermore, both PD98059 (ERK inhibitor) and SP600125 (JNK inhibitor) did not inhibit thrombin-induced cPLA 2a phosphorylation. Therefore, other platelet-activating mechanisms, such as Ca 2þ influx [9, 40, 41] and COX-1 activation by ERK2 [39] and serotonin release by JNK1 [20] , might have led to the suppression of ERK2 and JNK1 by G-Ro. Many compounds of ginseng, such as G-Ro, GRp4, Rg3-enriched red ginseng extract, and G-Rp1, inhibit the phosphorylation of MAPKs to attenuate Ca 2þ influx and serotonin release in platelets [26, 42, 43] .
We previously showed that G-Ro inhibits thrombin-induced Ca 2þ -dependent platelet-activating reactions, including granule secretion, fibrinogen binding, and fibrin clot retraction, by upregulating the cyclic adenosine monophosphate (cAMP)-dependent phosphorylation of IP 3 (Ser
1756
) and vasodilator-stimulated phosphoprotein (Ser 157 ) [44] . In this study, we observed that G-Ro attenuated thrombin-induced TXA 2 production by inhibiting AA release, and this effect was due to the inhibition of Ca In conclusion, G-Ro attenuates TXA 2 production by inhibiting p38-MAPK-mediated cPLA 2a phosphorylation and AA release. It also reduced the activities of microsomal COX-1 and TXAS in thrombin-activated human platelets. Combined with previous reports [30, 44, 48, 49] , G-Ro holds significant antiplatelet potential.
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